Penn Medicine's New Center for Personalized Diagnostics
When cancer specialists look at a patient’s tumor or cancer, they are just looking at a small piece of that patient’s diagnosis. For people with cancer, genetics and DNA testing can provide a clearer picture of why cancer develops to guide new, individualized treatments to stop the cancer from spreading.
Penn Medicine’s new Center for Personalized Diagnostics, a joint initiative of the department of Pathology and Laboratory Medicine in the Perelman School of Medicine and the Abramson Cancer Center, is diving deeper into each cancer patient’s tumor with next generation DNA sequencing.
These specialized tests can refine patient diagnoses with greater precision than standard imaging tests and blood work, all with an aim to broaden treatment options and improve their efficacy.
The Center for Personalized Diagnostics unites top experts in genomic analysis, bioinformatics, and cancer genetics – who use the most sensitive data analysis tools available to identify the rarest of mutations – with oncologists who treat patients and design clinical trials to test new therapies. Together, their efforts will provide cancer patients with cutting-edge diagnostic and therapeutic options.
Read the full press release announcing the new Center for Personalized Diagnostics at Penn Medicine to learn more about how these test results stand to change and improve cancer care.
The focus of the CPD's initial efforts has been toward developing two cancer gene sequencing panels: a custom hematologic malignancy panel and a solid tumor panel. The primary targets will include leukemias, and solid tumors, beginning with brain, melanoma, and lung tumors. The goal is to identify genomic alterations that allow clinicians to design and implement optimal treatment plans.
Learn more about the Center for Personalized Diagnostics here.
Penn Medicine’s new Center for Personalized Diagnostics, a joint initiative of the department of Pathology and Laboratory Medicine in the Perelman School of Medicine and the Abramson Cancer Center, is diving deeper into each cancer patient’s tumor with next generation DNA sequencing.
These specialized tests can refine patient diagnoses with greater precision than standard imaging tests and blood work, all with an aim to broaden treatment options and improve their efficacy.
The Center for Personalized Diagnostics unites top experts in genomic analysis, bioinformatics, and cancer genetics – who use the most sensitive data analysis tools available to identify the rarest of mutations – with oncologists who treat patients and design clinical trials to test new therapies. Together, their efforts will provide cancer patients with cutting-edge diagnostic and therapeutic options.
Read the full press release announcing the new Center for Personalized Diagnostics at Penn Medicine to learn more about how these test results stand to change and improve cancer care.
About the Center for Personalized Diagnostics
The Center for Personalized Diagnostics (CPD), a joint initiative by Penn Medicine's Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, integrates Molecular Genetics, Pathology Informatics, and Genomic Pathology for individualized patient diagnoses and to elucidate cancer treatment options for physicians.The focus of the CPD's initial efforts has been toward developing two cancer gene sequencing panels: a custom hematologic malignancy panel and a solid tumor panel. The primary targets will include leukemias, and solid tumors, beginning with brain, melanoma, and lung tumors. The goal is to identify genomic alterations that allow clinicians to design and implement optimal treatment plans.
Learn more about the Center for Personalized Diagnostics here.
Categories:
Center-for-personalized-diagnostics
0 comments:
Post a Comment